Lazard Upgrades XenoPort (XNPT) to Buy

September 23, 2008 9:05 AM EDT

Lazard Capital upgrades XenoPort (Nasdaq: XNPT) from Hold to Buy.

XenoPort, Inc., a biopharmaceutical company, focuses on developing internally-discovered product candidates that utilize the body's natural nutrient transporter mechanisms.


Related Categories

Upgrades

Stocks Mentioned

XNPT 16.05

-0.15 -0.93%
Volume: 432,628
Track XNPT


Related Entities


Add Your Comment